There are four dementia-specific medications approved in Australia – donepezil, galantamine, rivastigmine, and memantine.

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) founder Lars Lannfelt will be presented with the Lifetime Achievement Award in Alzheimer's Disease Therapeutic Research at the Clinical Trials for ...

Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research ...

Biogen Inc. (Nasdaq: BIIB) announced upcoming data presentations and programming at the Clinical Trials on Alzheimer’s ...

Then in 1890, Emil von Behring made the remarkable discovery that serum derived from the blood of horses injected with ...

Researchers use real-world data in the United States to evaluate the protective role of semaglutide against Alzherimer’s ...

For the second time in recent months, a U.K. agency said the limited benefits of a new Alzheimer’s drug do not justify its ...

U.K. regulators will reportedly recommend the NHS not cover Eli Lilly’s (LLY) donanemab for the treatment of early ...

Key Presentations and Symposia: Transitioning from Clinical Trial to Clinical Practice for Long-Term Lecanemab Treatment in Early Alzheimer's Disease: Perspectives from an Alzheimer's Disease ...

The most effective drug for Alzheimer’s will be blocked for use on the NHS on Wednesday. Regulators are expected to declare ...

Donanemab is a targeted antibody drug which slows down the early stages of Alzheimer’s. The drug, and another new drug for Alzheimer’s called lecanemab, have been billed as a huge step forward in ...